Thymalin: human cells are not a human rejuvenation trial
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Thymalin is a mixture of peptides isolated from thymus tissue. Its research asks how immune-cell development might be influenced. In one study, cultured human blood-forming stem cells changed several surface markers after exposure. The authors interpreted those changes as signs of differentiation. That experiment did not show fewer infections, longer life or reversal of immune ageing in patients. Older clinical reports exist, but strong claims require carefully controlled, independently replicated evidence. Because thymalin is an extract, its identity and composition also matter. Keep this discussion at the level of experimental immunology rather than promising an immune reset.

END CARD
Evidence first. Educational only. Sources in description.

SOURCES
[1] Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells
https://pmc.ncbi.nlm.nih.gov/articles/PMC7686446/
Primary human-cell culture study, not a human treatment trial

[2] Peptides of pineal gland and thymus prolong human life
https://pubmed.ncbi.nlm.nih.gov/14523363/
Historical human clinical report; title is an author claim, not an established conclusion

EVIDENCE LIMITATIONS
Thymalin is not synonymous with thymosin-alpha-1 or a single defined peptide.
Do not repeat the historical paper’s lifespan claim as an established result.
Changes in cell markers are surrogate laboratory observations.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
https://www.facebook.com/reel/1821181065756611/